Haemonetics (HAE) Scheduled to Post Quarterly Earnings on Thursday

Haemonetics (NYSE:HAE - Get Free Report) is set to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Haemonetics to post earnings of $0.88 per share for the quarter. Haemonetics has set its FY 2024 guidance at 3.900-4.000 EPS and its FY24 guidance at $3.90-4.00 EPS.Individual that wish to listen to the company's earnings conference call can do so using this link.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.10. The business had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company's revenue for the quarter was up 10.1% on a year-over-year basis. During the same period last year, the company earned $0.85 EPS. On average, analysts expect Haemonetics to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Haemonetics Trading Up 1.4 %

Shares of NYSE:HAE traded up $1.26 during trading on Thursday, hitting $93.39. The company had a trading volume of 345,709 shares, compared to its average volume of 451,888. The stock has a market cap of $4.74 billion, a price-to-earnings ratio of 37.96, a price-to-earnings-growth ratio of 2.17 and a beta of 0.34. Haemonetics has a one year low of $70.74 and a one year high of $95.26. The company has a fifty day simple moving average of $81.95 and a two-hundred day simple moving average of $82.74. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.92 and a quick ratio of 1.76.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HAE shares. Barrington Research reiterated an "outperform" rating and issued a $105.00 price target on shares of Haemonetics in a report on Friday, April 12th. TheStreet downgraded Haemonetics from a "b-" rating to a "c+" rating in a report on Thursday, February 29th. Finally, StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a report on Friday, March 22nd.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.